UY25268A1 - Inhibicion de la oxidacion de lipoproteinas - Google Patents
Inhibicion de la oxidacion de lipoproteinasInfo
- Publication number
- UY25268A1 UY25268A1 UY25268A UY25268A UY25268A1 UY 25268 A1 UY25268 A1 UY 25268A1 UY 25268 A UY25268 A UY 25268A UY 25268 A UY25268 A UY 25268A UY 25268 A1 UY25268 A1 UY 25268A1
- Authority
- UY
- Uruguay
- Prior art keywords
- hydroxylated
- cholesterol lowering
- chelation
- inhibition
- metal ions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se relaciona con un método para inhibir la oxidación de lipoproteínas en mamíferos, retardando o deteniendo así la aterogénesis. El método se vincula con el uso de derivados hidroxilados de agentes reductores del colesterol conocidos. Un método caracterizado por que el agente reductor de colesterol hidroxilado es atorvastatina, orto- o para-hidrixilada, gemfibrocil hidroxilado o fluvastatina hidroxilada, y por que la quelación de iones de metales de lipoproteínas en un mamífero caracterizado por que comprende administrar una cantidad inhibidora de la quelación de iones de metales, de un agente reductor de colesterol hidroxilado.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6688897P | 1997-11-25 | 1997-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25268A1 true UY25268A1 (es) | 1999-07-19 |
Family
ID=22072341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25268A UY25268A1 (es) | 1997-11-25 | 1998-11-24 | Inhibicion de la oxidacion de lipoproteinas |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6362236B1 (es) |
| EP (1) | EP1047421A2 (es) |
| JP (1) | JP2001523694A (es) |
| KR (3) | KR20050086975A (es) |
| CN (1) | CN1160068C (es) |
| AR (1) | AR015487A1 (es) |
| AU (1) | AU759376B2 (es) |
| BR (1) | BR9815039A (es) |
| CA (1) | CA2303864A1 (es) |
| CO (1) | CO4970835A1 (es) |
| HK (1) | HK1033095A1 (es) |
| HU (1) | HUP0004396A3 (es) |
| IL (1) | IL135154A (es) |
| IS (1) | IS5413A (es) |
| NO (1) | NO20002639L (es) |
| NZ (1) | NZ503598A (es) |
| PE (1) | PE134199A1 (es) |
| PL (1) | PL341397A1 (es) |
| TR (1) | TR200001522T2 (es) |
| TW (1) | TW552137B (es) |
| UY (1) | UY25268A1 (es) |
| WO (1) | WO1999026583A2 (es) |
| ZA (1) | ZA9810743B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7250304B2 (en) * | 2000-03-31 | 2007-07-31 | The Regents Of The University Of California | Functional assay of high-density lipoprotein |
| US20030040505A1 (en) * | 2000-03-31 | 2003-02-27 | The Regents Of The University Of California | Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions |
| US20030114497A1 (en) * | 2001-07-31 | 2003-06-19 | Laman Alani | Pharmaceutical compositions of amlodipine and atorvastatin |
| SI2404890T1 (sl) | 2003-01-23 | 2017-12-29 | Esperion Therapeutics Inc. | Hidroksilne spojine in sestavki za uravnavanje holesterola in sorodne uporabe |
| US20060194981A1 (en) * | 2005-02-26 | 2006-08-31 | Jass Paul A | Process for preparation of probucol derivatives |
| WO2006104399A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Copper antagonist compositions |
| EP3578177A1 (en) | 2008-09-02 | 2019-12-11 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| RU2538691C2 (ru) | 2009-04-29 | 2015-01-10 | Амарин Фарма, Инк. | Стабильные фармацевтические композиции и способы их применения |
| EP3563842A1 (en) | 2009-04-29 | 2019-11-06 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| LT3318255T (lt) | 2009-06-15 | 2021-05-25 | Amarin Pharmaceuticals Ireland Limited | Kompozicijos ir būdai, skirti insulto gydymui pacientui kartu su statinų terapija |
| CA2775339C (en) | 2009-09-23 | 2017-03-28 | Amarin Corporation Plc | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | METHODS OF TREATING HYPERTRIGLYCERIDEMIA |
| EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
| EP4342546A3 (en) | 2012-06-29 | 2024-05-22 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| KR101665180B1 (ko) | 2014-07-01 | 2016-10-14 | 순천향대학교 산학협력단 | 아포지단백질 a-i 돌연변이체 g59v를 포함하는 항산화성 펩타이드 및 이를 포함하는 항산화 조성물 |
| MX2017011499A (es) | 2015-03-13 | 2018-03-26 | Esperion Therapeutics Inc | Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. |
| MA41793A (fr) | 2015-03-16 | 2018-01-23 | Esperion Therapeutics Inc | Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| FI4056176T3 (fi) | 2018-09-24 | 2024-05-30 | Amarin Pharmaceuticals Ie Ltd | Menetelmät kardiovaskulaaristen tapahtumien riskin pienentämiseksi tutkittavassa |
| KR20220024816A (ko) | 2019-06-21 | 2022-03-03 | 에스페리온 테라피유틱스 인코포레이티드 | 벰페도산 및 그의 조성물을 제조하는 방법 |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5385929A (en) * | 1994-05-04 | 1995-01-31 | Warner-Lambert Company | [(Hydroxyphenylamino) carbonyl] pyrroles |
-
1998
- 1998-11-04 EP EP98959378A patent/EP1047421A2/en not_active Withdrawn
- 1998-11-04 HU HU0004396A patent/HUP0004396A3/hu unknown
- 1998-11-04 PL PL98341397A patent/PL341397A1/xx not_active Application Discontinuation
- 1998-11-04 US US09/485,250 patent/US6362236B1/en not_active Expired - Fee Related
- 1998-11-04 KR KR1020057014824A patent/KR20050086975A/ko not_active Application Discontinuation
- 1998-11-04 CA CA002303864A patent/CA2303864A1/en not_active Abandoned
- 1998-11-04 IL IL13515498A patent/IL135154A/xx not_active IP Right Cessation
- 1998-11-04 WO PCT/US1998/023483 patent/WO1999026583A2/en not_active Application Discontinuation
- 1998-11-04 BR BR9815039-1A patent/BR9815039A/pt not_active Application Discontinuation
- 1998-11-04 AU AU15188/99A patent/AU759376B2/en not_active Ceased
- 1998-11-04 JP JP2000521788A patent/JP2001523694A/ja not_active Abandoned
- 1998-11-04 KR KR10-2000-7005641A patent/KR100539644B1/ko not_active IP Right Cessation
- 1998-11-04 CN CNB988112671A patent/CN1160068C/zh not_active Expired - Fee Related
- 1998-11-04 TR TR2000/01522T patent/TR200001522T2/xx unknown
- 1998-11-04 KR KR1020057021847A patent/KR100586754B1/ko not_active IP Right Cessation
- 1998-11-04 NZ NZ503598A patent/NZ503598A/en unknown
- 1998-11-24 ZA ZA9810743A patent/ZA9810743B/xx unknown
- 1998-11-24 CO CO98069227A patent/CO4970835A1/es unknown
- 1998-11-24 AR ARP980105959A patent/AR015487A1/es unknown
- 1998-11-24 UY UY25268A patent/UY25268A1/es not_active Application Discontinuation
- 1998-11-24 PE PE1998001143A patent/PE134199A1/es not_active Application Discontinuation
- 1998-11-25 TW TW087119590A patent/TW552137B/zh not_active IP Right Cessation
-
2000
- 2000-03-24 IS IS5413A patent/IS5413A/is unknown
- 2000-05-23 NO NO20002639A patent/NO20002639L/no unknown
-
2001
- 2001-06-04 HK HK01103822A patent/HK1033095A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1033095A1 (en) | 2001-08-17 |
| KR100539644B1 (ko) | 2005-12-29 |
| HUP0004396A2 (hu) | 2001-06-28 |
| WO1999026583A3 (en) | 1999-12-09 |
| IS5413A (is) | 2000-03-24 |
| PE134199A1 (es) | 2000-01-20 |
| ZA9810743B (en) | 1999-05-31 |
| NZ503598A (en) | 2002-06-28 |
| WO1999026583A2 (en) | 1999-06-03 |
| KR20050113288A (ko) | 2005-12-01 |
| TR200001522T2 (tr) | 2000-12-21 |
| BR9815039A (pt) | 2001-03-20 |
| CA2303864A1 (en) | 1999-06-03 |
| KR20050086975A (ko) | 2005-08-30 |
| KR20010032401A (ko) | 2001-04-16 |
| AU759376B2 (en) | 2003-04-10 |
| AR015487A1 (es) | 2001-05-02 |
| JP2001523694A (ja) | 2001-11-27 |
| HUP0004396A3 (en) | 2003-04-28 |
| CN1160068C (zh) | 2004-08-04 |
| NO20002639D0 (no) | 2000-05-23 |
| CN1279605A (zh) | 2001-01-10 |
| IL135154A0 (en) | 2001-05-20 |
| CO4970835A1 (es) | 2000-11-07 |
| IL135154A (en) | 2005-05-17 |
| KR100586754B1 (ko) | 2006-06-08 |
| PL341397A1 (en) | 2001-04-09 |
| TW552137B (en) | 2003-09-11 |
| US6362236B1 (en) | 2002-03-26 |
| AU1518899A (en) | 1999-06-15 |
| NO20002639L (no) | 2000-05-23 |
| EP1047421A2 (en) | 2000-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25268A1 (es) | Inhibicion de la oxidacion de lipoproteinas | |
| PT971713E (pt) | Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao | |
| BR0114758A (pt) | Inibidores do receptor ep4 para tratamento de artrite reumatóide | |
| BR9916518A (pt) | Método para tratar ou prevenir um distúrbio de neoplasia em um mamìfero em necessidade de tal tratamento ou prevenção, e, combinação compreendendo um inibidor de ciclooxigenase-2 e um ou mais agentes anti-neoplásticos | |
| UY25322A1 (es) | Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis | |
| DK0840732T3 (da) | Substituerede benzolactamforbindelser som substans P-antagonister | |
| BR9812753A (pt) | Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica | |
| BR9916484A (pt) | Combinações de inibidores do transporte de ácido biliar ileal e de agentes sequestrantes de ácido biliar em indicações cardiovasculares | |
| BR9814923A (pt) | Método para tratamento de doença de alzheimer | |
| BR0111601A (pt) | Método para o tratamento de doença cardiovascular | |
| BR0110506A (pt) | Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose | |
| TR200100774T2 (tr) | Bir aP2 önleyicisinin ve kombinasyonunun kullanıldığı aterosklerozis tedavi yöntemi | |
| BR9809115A (pt) | Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt | |
| AU2001275228A1 (en) | Cancer treatment composition containing an anti-neoplastic agent and a pde4 inhibitor | |
| CO5261493A1 (es) | Procedimiento y compuestos para la inhibicion de la mrp1 | |
| ES2183303T3 (es) | Quelatos metalicos de derivados macrociclicos poliaminocarboxilicos y su aplicacion en la formacion de imagenes para diagnostico. | |
| BRPI0409551A (pt) | derivados de fosfato e método para a fosforilação de um composto que tem um grupo hidróxi secundário | |
| NO20001413L (no) | Synergistisk sammensetning samt fremgangsmÕter ved behandling av neoplasier og svulster samt for Õ restaurere eller forsterke hematopoese | |
| CU20000140A7 (es) | Combinaciones de estatina-carboxialquileter | |
| DK1035859T3 (da) | Anvendelse af phospholipidkomplekser fra ekstrakter af Vitis vinifera som anti-atherosklerotiske midler | |
| ES2046889T3 (es) | Metodo para inhibicion de la maduracion folicular. | |
| BR9811003A (pt) | processo para a prevenção ou tratamento de prurido em um paciente mamìfero | |
| ES2196559T3 (es) | Inhibidores de farnesil transferasa en combinacion con inhibidores de hmg coa reductasa para el tratamiento del cancer. | |
| PT876158E (pt) | Nova utilizacao de um inibidor de eca para o tratamento de sintomas dispepticos | |
| ES2188791T3 (es) | Composicion fungicida sinergica que comprende un compuesto analogo de la estrobilurina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RDES | Application refused |
Effective date: 20010525 |